title: Study results on the use of different therapies for the treatment of vaginitis in hospitalised pregnant women.
abstract: OBJECTIVE
  During pregnancy, many women experience vaginal infections due to a weakened immune system and changes in hormonal status. Treating these infections is of crucial importance, because women are at high risk for serious complications such as preterm birth and late miscarriage. For this reason, the present study was conducted to investigate the effectiveness of octenidine dihydrochloride/phenoxyethanol (OHP) in comparison to antimicrobial therapies in pregnant women in hospital suffering from different types of vaginitis.
  
  
  METHODS
  A total of 1,000 patients were divided into 4 different groups according to their type of vaginal infection after smear analyses. Each group was again divided into two subgroups receiving treatment with OHP or antimicrobial therapies with neomycin/polymyxin B/nystatin, metronidazole or miconazole vaginal tablets.
  
  
  RESULTS
  The most frequent causes of vaginitis were unspecific bacterial infections (42.4 %) and vaginal candidiasis (44.8 %). The average time needed to obtain negative results from smear analyses was significantly shorter when treated with OHP, both in patients with bacterial vaginosis (BV) or vaginal candidiasis (VC) compared to antimicrobial therapy (1.7 ± 0.8 vs. 2.3 ± 1.1 days; 2.3 ± 1.4 vs. 3.4 ± 1.6 days; both p < 0.001). Equally, the maximum number of days until negative results were detected was significantly lower with OHP compared to antimicrobial therapy (BV: 3 vs. 5 days; VC: 5 vs. 7 days).
  
  
  CONCLUSIONS
  OHP has a great effect in the treatment of vaginitis during pregnancy and thus should be an integral part of standard therapy regimens.
authors: Policlinic "Novakov et al.", Kosovska 26, 21000, Novi Sad, Serbia, aleksandranovakov@gmail.com.
authors: Aleksandra
authors: A
authors: Novakov Mikić
authors: Sinisa
authors: S
authors: Stojic
mesh_terms: D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D005026:Ethylene Glycols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007097:Imines; D008795:Metronidazole; D008825:Miconazole; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000382:microbiology; D047928:Premature Birth; D011446:Prospective Studies; D011725:Pyridines / Q000627:therapeutic use*; D055771:Serbia; D016896:Treatment Outcome; D014627:Vaginitis / Q000188:drug therapy* / Q000382:microbiology; D016585:Vaginosis, Bacterial / Q000188:drug therapy; D014848:Vulvovaginitis / Q000188:drug therapy
chemical_list: D000890:Anti-Infective Agents; D005026:Ethylene Glycols; D007097:Imines; D011725:Pyridines; D008795:Metronidazole; D008825:Miconazole; C005398:phenoxyethanol; C034213:octenidine